# Lumbrokinase vs Placebo in Moderate-to-Severe Ischemic Stroke

Study · id `cardio:ct-nct07763405` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07763405](<https://clinicaltrials.gov/study/NCT07763405>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07763405

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1196 participants.

## Technical summary

Registry record NCT07763405. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-01 (anticipated); primary completion 2028-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1196 participants (planned count; ClinicalTrials.gov record NCT07763405, source copy `cardio:ctgov-nct07763405-2026-08-13`, retrieved 2026-10-26)
- Planned start: 2026-11-01 (anticipated) (ClinicalTrials.gov record NCT07763405, source copy `cardio:ctgov-nct07763405-2026-08-13`, retrieved 2026-10-26)
- Primary completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT07763405, source copy `cardio:ctgov-nct07763405-2026-08-13`, retrieved 2026-10-26)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT07763405, source copy `cardio:ctgov-nct07763405-2026-08-13`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07763405-2026-08-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Lumbrokinase vs Placebo in Moderate-to-Severe Ischemic Stroke
- Condition: Ischemic Stroke, Acute
- Intervention (Drug): Lumbrokinase
- Intervention (Drug): Lumbrokinase Placebo
- Lead sponsor: Xinqiao Hospital of Chongqing
- Lead sponsor class: OTHER
- Collaborator: The First Affiliated Hospital of Nanchang University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Xinqiao Hospital of Chongqing (`cardio:org-xinqiao-hospital-of-chongqing`)
- Registry lists this organization as a collaborator: The First Affiliated Hospital of Nanchang University (`cardio:org-the-first-affiliated-hospital-of-nanchang-university`)

## Provenance

Content hash: dc67123519a0ade8c41c66a1d9bdd26707a13fd54fe594c7ffbd09fc1ec168a8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
